Mandy Aldwin-Easton
Mandy Aldwin-Easton has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Edel A. O'TOole
Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London, London, UK
4 shared publications - Antoni Gostynski
Department of Dermatology, Maastricht UMC+ Centre of Expertise for Genodermatoses, Maastricht University Medical Centre+ , Maastricht
3 shared publications - Janice Schwartz
Pachyonychia Congenita Project, Salt Lake City, Utah, USA
3 shared publications - Akemi Ishida‐Yamamoto
Department of Dermatology Asahikawa Medical University Asahikawa Japan
2 shared publications - Alain Hovnanian
INSERM UMR 1163, Laboratory of genetic skin diseases, Imagine Institute of Genetic Diseases, University Paris Cité and Department of Genomic Medicine of Rare Diseases, AP-HP, Hôpital Necker-Enfants Malades, Paris, France
2 shared publications - Amy S. Paller
Departments of Dermatology and Pediatrics Northwestern University Feinberg School of Medicine Chicago Illinois USA
2 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (6) , 964-974
A national epidemiological study of inherited ichthyoses in England from 1998 to 2024
Background: Ichthyoses (epidermal differentiation disorders) cause significant morbidity and mortality; however, national epidemiological data that link diagnoses of ichthyoses with systemic comorbidities are lacking. Objectives: To report epidemiological data on inherited ichthyoses in England, together with patient-level comorbidities and genetic testing status. Methods: This national retrospective cohort study identified ichthyosis case records from healthcare databases in England, using International Classification of Diseases, 10th Revision (ICD-10) codes from 1998 to 2024. Cohort demographics, comorbidities, genetic testing data and mortality data were extracted from routinely collected National Health Service data. Results: We identified 4330 patients with ichthyosis, of whom 3758 were categorized as having a rare ichthyosis. The prevalence of rare ichthyoses was 51.6 per million (95% confidence interval 49.7–53.5). Compared with the reference population, the overall cohort was younger [median age 22 (interquartile range 11–49) vs. 41 years], more likely to identify as Asian (17.1% vs. 9.6%; P < 0.001) and were more frequently in the most deprived quintiles (48.1% vs. 40.0%; P < 0.001). The rates of comorbidities, including asthma, inflammatory arthropathies and atrial fibrillation, were higher than in the reference population. Nineteen per cent of deaths occurred before the age of 25 years compared with 1% of deaths at this age threshold in the reference population (P < 0.001). Genetic testing data revealed a low proportion of tested cases; pathogenic variants in genes known to cause ichthyosis were found in 56.3% of the tested cases (n = 90/160). Conclusions: We report an increased range of comorbidities in patients living with rare ichthyoses, highlighting the systemic burden in patients categorized as having nonsyndromic ichthyosis. These data inform healthcare planning, research design and the redressing of inequities of care. An author video to accompany this article is available online.
- 21 July 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (6) , 964-974
Open AccessA national epidemiological study of inherited ichthyoses in England from 1998 to 2024
Background: Ichthyoses (epidermal differentiation disorders) cause significant morbidity and mortality; however, national epidemiological data that link diagnoses of ichthyoses with systemic comorbidities are lacking. Objectives: To report epidemiological data on inherited ichthyoses in England, together with patient-level comorbidities and genetic testing status. Methods: This national retrospective cohort study identified ichthyosis case records from healthcare databases in England, using International Classification of Diseases, 10th Revision (ICD-10) codes from 1998 to 2024. Cohort demographics, comorbidities, genetic testing data and mortality data were extracted from routinely collected National Health Service data. Results: We identified 4330 patients with ichthyosis, of whom 3758 were categorized as having a rare ichthyosis. The prevalence of rare ichthyoses was 51.6 per million (95% confidence interval 49.7–53.5). Compared with the reference population, the overall cohort was younger [median age 22 (interquartile range 11–49) vs. 41 years], more likely to identify as Asian (17.1% vs. 9.6%; P < 0.001) and were more frequently in the most deprived quintiles (48.1% vs. 40.0%; P < 0.001). The rates of comorbidities, including asthma, inflammatory arthropathies and atrial fibrillation, were higher than in the reference population. Nineteen per cent of deaths occurred before the age of 25 years compared with 1% of deaths at this age threshold in the reference population (P < 0.001). Genetic testing data revealed a low proportion of tested cases; pathogenic variants in genes known to cause ichthyosis were found in 56.3% of the tested cases (n = 90/160). Conclusions: We report an increased range of comorbidities in patients living with rare ichthyoses, highlighting the systemic burden in patients categorized as having nonsyndromic ichthyosis. These data inform healthcare planning, research design and the redressing of inequities of care. An author video to accompany this article is available online.
- 2 July 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (9) , 2127-2130
The Importance of Shared Patient Voices in Advancing Science for Genodermatoses on a Global Scale
- 2 July 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (9) , 2127-2130
The Importance of Shared Patient Voices in Advancing Science for Genodermatoses on a Global Scale
- Top Cited PapersOpen Access
- 1 May 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 619-641
Nonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Epidermal differentiation disorders (EDDs) encompass inherited conditions characterized by abnormal epidermal differentiation, including nonsyndromic and syndromic subtypes with more extensive cutaneous involvement or palmoplantar keratoderma. Nonsyndromic EDDs (nEDDs) are defined as disorders that primarily affect large areas of skin and adnexal structures without alterations in extracutaneous tissues resulting from the underlying genetic change. To facilitate the development of targeted therapies and to provide clinicians with clearer therapeutic guidance, we have developed a new nomenclature for EDDs that includes the causative altered gene and the nEDD subgroup designation, sometimes with a clinical or histological descriptor or acronym. Historically, many nEDDs have been named on the basis of phenotypic characteristics or associations that are now considered outdated or inappropriate. For example, the term ‘harlequin ichthyosis’ evokes potentially stigmatizing images. Similarly, the word ‘ichthyosis’ is derived from the Greek ichthys, meaning fish, and the Greek hystrix, meaning porcupine, further emphasizing the need to abandon derogatory terminology. As a result, the clinical relevance of the previous classification, which included eponymous and/or descriptive titles, has diminished. In the new, gene-based classification, old terms considered pejorative, such as ichthyosis, vulgaris, hystrix and harlequin have been eliminated and eponyms have been replaced. Among the 53 genetically distinct nEDDs are conditions formerly known as autosomal recessive congenital ichthyosis, erythrokeratodermia variabilis et progressiva, Hailey–Hailey disease and Darier–White disease. This review outlines the updated nomenclature and classifications of nEDDs, linked to detailed clinical descriptions and representative photographs to guide practitioners.
- 1 May 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 619-641
Top Cited PapersOpen AccessNonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Epidermal differentiation disorders (EDDs) encompass inherited conditions characterized by abnormal epidermal differentiation, including nonsyndromic and syndromic subtypes with more extensive cutaneous involvement or palmoplantar keratoderma. Nonsyndromic EDDs (nEDDs) are defined as disorders that primarily affect large areas of skin and adnexal structures without alterations in extracutaneous tissues resulting from the underlying genetic change. To facilitate the development of targeted therapies and to provide clinicians with clearer therapeutic guidance, we have developed a new nomenclature for EDDs that includes the causative altered gene and the nEDD subgroup designation, sometimes with a clinical or histological descriptor or acronym. Historically, many nEDDs have been named on the basis of phenotypic characteristics or associations that are now considered outdated or inappropriate. For example, the term ‘harlequin ichthyosis’ evokes potentially stigmatizing images. Similarly, the word ‘ichthyosis’ is derived from the Greek ichthys, meaning fish, and the Greek hystrix, meaning porcupine, further emphasizing the need to abandon derogatory terminology. As a result, the clinical relevance of the previous classification, which included eponymous and/or descriptive titles, has diminished. In the new, gene-based classification, old terms considered pejorative, such as ichthyosis, vulgaris, hystrix and harlequin have been eliminated and eponyms have been replaced. Among the 53 genetically distinct nEDDs are conditions formerly known as autosomal recessive congenital ichthyosis, erythrokeratodermia variabilis et progressiva, Hailey–Hailey disease and Darier–White disease. This review outlines the updated nomenclature and classifications of nEDDs, linked to detailed clinical descriptions and representative photographs to guide practitioners.
- Top Cited PapersOpen Access
- 4 April 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 592-618
Syndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Since the 2010 classification of ichthyoses, our understanding of hereditary epidermal differentiation disorders (EDDs) has markedly increased, allowing for consideration of new therapeutic targets based on disease pathogenesis. A new gene- and protein product function-based classification focuses on shared mechanisms of disease pathogenesis, with the possibility that grouped disorders may respond similarly to new therapeutics. These EDDs have been subdivided into syndromic (sEDD), nonsyndromic with features limited to skin and appendages, and predominantly palmoplantar skin involvement (nonsyndromic and syndromic). sEDDs have clinically important extracutaneous features related to the gene alteration. Often, recognition based on skin manifestations facilitates early gene-based diagnosis, discussion of prognosis, genetic counselling and the initiation of therapy. All sEDDs are rare; the most common are STS-sEDD (formerly known as X-linked ichthyosis) and SPINK5-sEDD (formerly known as Netherton syndrome). Given the rarity, frequent association with early demise and variable clinical features of sEDDs, the natural history of the diseases with advancing age and genotype–phenotype relationships are poorly defined. Of the 51 sEDDs, associated neurological (n = 36; 71%) and/or ophthalmological (n = 25; 49%) findings are most common, and 39% (n = 20) have associated hair abnormalities. The widespread use of topical lovastatin for cholesterol synthesis-related sEDDs represents the prototype of pathogenesis-based therapy. This concept of upstream inhibition to prevent metabolite accumulation and supplementation with the pathway end product potentially applies to other sEDDs, such as those affecting ceramide synthesis and transport. Topical or systemically administered inhibition of activated pathways is another potential approach, exemplified by the emerging treatment of SPINK5-sEDD with kallikrein inhibitors. Many sEDDs may be amenable to gene editing or the introduction of functional cDNA. However, even systemic treatments targeting cutaneous diseases may not address extracutaneous manifestations that arise during embryological development.
- 4 April 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 592-618
Top Cited PapersOpen AccessSyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Since the 2010 classification of ichthyoses, our understanding of hereditary epidermal differentiation disorders (EDDs) has markedly increased, allowing for consideration of new therapeutic targets based on disease pathogenesis. A new gene- and protein product function-based classification focuses on shared mechanisms of disease pathogenesis, with the possibility that grouped disorders may respond similarly to new therapeutics. These EDDs have been subdivided into syndromic (sEDD), nonsyndromic with features limited to skin and appendages, and predominantly palmoplantar skin involvement (nonsyndromic and syndromic). sEDDs have clinically important extracutaneous features related to the gene alteration. Often, recognition based on skin manifestations facilitates early gene-based diagnosis, discussion of prognosis, genetic counselling and the initiation of therapy. All sEDDs are rare; the most common are STS-sEDD (formerly known as X-linked ichthyosis) and SPINK5-sEDD (formerly known as Netherton syndrome). Given the rarity, frequent association with early demise and variable clinical features of sEDDs, the natural history of the diseases with advancing age and genotype–phenotype relationships are poorly defined. Of the 51 sEDDs, associated neurological (n = 36; 71%) and/or ophthalmological (n = 25; 49%) findings are most common, and 39% (n = 20) have associated hair abnormalities. The widespread use of topical lovastatin for cholesterol synthesis-related sEDDs represents the prototype of pathogenesis-based therapy. This concept of upstream inhibition to prevent metabolite accumulation and supplementation with the pathway end product potentially applies to other sEDDs, such as those affecting ceramide synthesis and transport. Topical or systemically administered inhibition of activated pathways is another potential approach, exemplified by the emerging treatment of SPINK5-sEDD with kallikrein inhibitors. Many sEDDs may be amenable to gene editing or the introduction of functional cDNA. However, even systemic treatments targeting cutaneous diseases may not address extracutaneous manifestations that arise during embryological development.